Peptide Skincare & BeautySkin science and ingredient guides

Skin science article

What could cause a lump under the skin above my lip? | Ubie Doctor's Note

What could cause a lump under the skin above my lip? Reviewed by Tomas Diaz, MD Emergency Medicine A lump above your lip may be caused by different conditions including benign (non-cancerous) growths like cysts, cancers, or infections. Important Next Steps Not

By Peptide Skincare & Beauty Editorial TeamPublished

What could cause a lump under the skin above my lip?

Reviewed by Tomas Diaz, MD

Emergency Medicine

A lump above your lip may be caused by different conditions including benign (non-cancerous) growths like cysts, cancers, or infections.

Important Next Steps

Not seeing your question? No worries.

Explanation

Lumps above the lip can have different characteristics depending on their cause. For instance, benign growths like cysts tend to be soft and movable, while cancerous lumps are often firm and fixed in place. The location, size, and any associated symptoms like pain or redness can also provide important clues about the underlying cause. Common causes of swelling above the lip include:

Sebaceous cysts - These are small, fluid-filled lumps that develop when oil-producing glands become blocked. They're usually painless and feel soft to touch.

Mucous cysts - These fluid-filled sacs can form when salivary glands become blocked, creating a bluish, dome-shaped bump.

Infections due to viruses or bacteria (which can enter under the skin from minor trauma or shaving) can lead to bumps above the lips. Similarly, allergies (including to ingredients in cosmetics) can cause swelling around the lips. If you identify a lump that is persistent, painful, or growing, it is best to have it evaluated by a healthcare provider.

(References)

Gelidan AG, Arab K. Rare upper lip pleomorphic adenoma presents as cutaneous skin lesion: Case report. Int J Surg Case Rep. 2021 Aug;85:106142. doi: 10.1016/j.ijscr.2021.106142. Epub 2021 Jun 29. PMID: 34265588; PMCID: PMC8281655.

Stojanovic S, Jovanovic M, Vuckovic N. Unusual growth of upper lip squamous cell carcinoma: a case report. Iran Red Crescent Med J. 2015 Mar 31;17(3):e13478. doi: 10.5812/ircmj.13478. PMID: 26019891; PMCID: PMC4441773.

Lee YS, Sim HS, Lee SK. Actinomycosis of the upper lip. Ann Dermatol. 2011 Sep;23 Suppl 1(Suppl 1):S131-4. doi: 10.5021/ad.2011.23.S1.S131. Epub 2011 Sep 30. PMID: 22028560; PMCID: PMC3199410.

Tell your friends about us.

We would love to help them too.

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Learn more about symptoms

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.

The reference edit

Ingredients, questions
& further reading.

Connected source records selected through this article’s public topic index.

04

Ask the journal

Related questions

01Why Was It Approved?

The FDA's approval is based on a placebo‑controlled study that included people 12 or older with HES who had had at least one HES flare in the past year, with most people having at least two flares in the past year. During the study, everyone stayed on their usual therapy. People with a known non-blood-related cause of HES or a gene marker called FIP1L1‑PDGFRA were not included. Compared with a placebo, Fasenra delayed the first HES flare. It also cut the risk of a first flare by about 65%. During about 24 weeks of treatment, fewer people had flares and the overall number of flares was lower, compared with those taking a placebo. By the end of the study, people using Fasenra also reported less fatigue. The most common side effects were headaches, allergic reactions such as hives or rashes, and a flu‑like illness.

Source · www.webmd.com ⟶
02Why Was It Approved?

This approval was based on a clinical study of 531 adults whose multiple myeloma returned after receiving other treatments. These patients were split into two groups. One group received the new under-the-skin injection, and the other group received the older IV version. Everyone also took two other common cancer medicines. The study wanted to see if the new injection worked as well as the IV drug. In both groups, about 71% of patients had their cancer shrink or disappear. This showed that both options are similarly effective at fighting cancer. The study also showed that the under-the-skin injection offered benefits for patient comfort. Only 1.5% of patients who got the under-the-skin injection had whole-body reactions to the injection. In comparison, 25% of patients in the IV group had those reactions. Less than 1% of patients getting the under-the-skin injection had skin reactions where the needle went in, and these were mostly minor. Common side effects for both groups included fatigue, diarrhea, lung infections, and low blood cell counts.

Source · www.webmd.com ⟶

Continue reading

Related articles